CF AMR Syndicate Wins Most Impactful Industry Collaboration of the Year Award
The Cystic Fibrosis Antimicrobial Resistance (CF AMR) Syndicate was named winner of the Most Impactful Industry Collaboration of the Year at last night’s OBN Awards.
The CF AMR Syndicate is a cross-sector initiative that brings together leading experts in CF and AMR from industry, academia and the clinic with people with CF. It was established in 2019 and is jointly managed by Medicines Discovery Catapult, Cystic Fibrosis Trust and LifeArc.
The CF AMR Syndicate won the award in recognition of its cross-sector collaborative approach, which involves working closely with people with CF, clinicians, regulators, academics and industry.
CF affects more than 11,300 people in the UK and new diagnostics and antimicrobials are urgently needed. The CF AMR Syndicate seeks to address this. It draws on the collective expertise of managing partners and the wider cross-sector expertise of the CF AMR community to deliver a collaborative approach that could prove pivotal in unlocking future breakthroughs.
Dr Beverley Isherwood, Strategy Leader – Infectious Diseases at Medicines Discovery Catapult, said: “The CF AMR Syndicate is extremely proud of its collaborative approach to address the challenges faced by people with CF. We are thrilled to have won this award in recognition of our work and ongoing commitment to improving outcomes for people with CF.”
Dr Catherine Kettleborough, LifeArc’s Chronic Respiratory Infection Translational Challenge Lead, said: “The CF AMR Syndicate demonstrates the incredible impact that working together across sectors can achieve. This award reflects the collective dedication of our partners to drive progress in addressing the urgent challenges of antimicrobial resistance in cystic fibrosis, ultimately improving lives for those affected.”
Dr Paula Sommer, Head of Research at Cystic Fibrosis Trust, said: “It’s an honour to win this award, recognising the CF AMR Syndicate’s work to bring together new research and develop treatments with the potential to benefit people with CF.
“AMR is a risk for everyone, but people living with CF are particularly vulnerable as they rely on antimicrobial medicines to treat lung infections. There’s still so much more to do to stop cystic fibrosis damaging and shortening lives.”
OBN is a membership organisation that brings together over 380 of the UK’s emerging life science companies, corporate partners, and investors.
The OBN Awards are a highly regarded and sought-after awards programme for the life sciences, designed to celebrate innovation and outstanding achievement across all corners of the industry.
Read OBN’s press release for full details of all the winners
